Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. (Q51139133)
Jump to navigation
Jump to search
scientific article published on 13 February 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. |
scientific article published on 13 February 2017 |
Statements
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia (English)
Christopher E Mason
Cem Meydan
Alan H Shih
Kaitlyn Shank
Francine E Garrett-Bakelman
Patrick S Ward
Abbas Nazir
Eytan M Stein
Kristina Knapp
Jacob Glass
Jeremy Travins
Kim Straley
Camelia Gliser
Katharine Yen
Ari Melnick
13 February 2017
1 reference
1 reference